|
|
Volumn 126, Issue 19, 2001, Pages 547-550
|
|
Switch from ACE inhibitor, calcium channel blocker or β-blocker to candesartan cilexetil: Better efficacy and tolerability - SWITCH study (German part);Wechsel von ACE-hemmer, ca-antagonist oder β-blocker zu candesartancilexetil: Bessere wirksamkeit und verträglichkeit - SWITCH-studie (deutscher studienteil)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
CALCIUM CHANNEL BLOCKING AGENT;
CANDESARTAN HEXETIL;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
ADULT;
ARTICLE;
BLOOD PRESSURE REGULATION;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIASTOLIC BLOOD PRESSURE;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
ESSENTIAL HYPERTENSION;
FEMALE;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
MONOTHERAPY;
OUTPATIENT CARE;
RANDOMIZED CONTROLLED TRIAL;
ADOLESCENT;
ADRENERGIC BETA-ANTAGONISTS;
ADULT;
AGED;
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
ANTIHYPERTENSIVE AGENTS;
BENZIMIDAZOLES;
BIPHENYL COMPOUNDS;
CALCIUM CHANNEL BLOCKERS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
HUMANS;
HYPERTENSION;
MALE;
MIDDLE AGED;
PROSPECTIVE STUDIES;
TETRAZOLES;
TREATMENT OUTCOME;
|
|
EID: 0035843826
PISSN: 00120472
EISSN: None
Source Type: Journal
DOI: 10.1055/s-2001-13808 Document Type: Article |
|
Times cited : (9)
|
|
References (11)
|
